Related Experiment Video

Updated: Jul 6, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
06:55

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents

Published on: December 2, 2015

Depression and heart disease: therapeutic implications

Trudie C Somberg1, Rohit R Arora

  • 1George Washington University, Washington, DC, USA.

Cardiology
|April 1, 2008
PubMed

Insights

Depression and coronary artery disease (CAD) comorbidity increases cardiovascular mortality. Selective serotonin reuptake inhibitors (SSRIs) may reduce this risk by improving platelet function in depressed patients with CAD.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Comorbidity of depression and coronary artery disease (CAD) is linked to increased cardiovascular mortality.
  • Existing treatments for depression may exacerbate cardiac issues or be poorly tolerated by CAD patients.

Purpose of the Study:

  • To review literature on the link between depression and CAD.
  • To explore mechanisms underlying the increased cardiovascular mortality in patients with both conditions.
  • To evaluate the potential benefits of selective serotonin reuptake inhibitors (SSRIs) in this population.

Main Methods:

  • Literature review of studies examining depression and CAD.
  • Analysis of potential pathophysiological links, including medication side effects and platelet abnormalities.
  • Examination of findings from trials like SADHART and ENRICHD regarding SSRI use.

Main Results:

  • Tricyclic antidepressants can cause cardiac arrhythmias.
  • Serotonin abnormalities in platelets may contribute to both depression and increased platelet aggregation.
  • Vascular depression due to atherosclerosis is another potential mechanism.
  • Depressed patients may exhibit lower medication compliance.
  • SSRIs may reduce cardiovascular mortality in depressed patients, potentially by addressing platelet abnormalities.

Conclusions:

  • The comorbidity of depression and CAD presents significant cardiovascular risks.
  • SSRIs show promise in mitigating cardiovascular mortality in depressed CAD patients, possibly through effects on platelet serotonin.
  • Further research into SSRI mechanisms for treating comorbid depression and CAD is warranted.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...